George Hajjar

George Hajjar

Auto-generated profile, based on publicly available information

George Hajjar

Department of Medical Oncology and Therapeutics Research, City of Hope, Mission Hills, CA 91345, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LFLinda Bosserman MD, PhD, AASECT, FACP, FASCO
Linda Bosserman MD, PhD, AASECT, FACP, FASCO
IMIsa Mambetsariev
Isa Mambetsariev
CLColton Ladbury
Colton Ladbury
ABAfsaneh Barzi
Afsaneh Barzi
DJDeron Johnson
Deron Johnson
Ravi SalgiaRavi Salgia
Ravi Salgia
The complexity of cancer care requires integrated and continuous support to deliver appropriate care. An expert network with complementary expertise and the capability of multidisciplinary care is an integral part of contemporary oncology care. Appropriate infrastructure is necessary to empower this network to deliver personalized precision care to their patients. Providing decision support as cancer care becomes exponentially more complex with new diagnostic and therapeutic choices remains challenging. City of Hope has developed a Pyramidal Decision Support Framework to address these challenges, which were exacerbated by the COVID pandemic, health plan restrictions, and growing geographic site diversity. Optimizing efficient and targeted decision support backed by multidisciplinary cancer expertise can improve individual patient treatment plans to achieve improved care and survival wherever patients are treated.

Verified
Journal Article
Open access
PDF file
MKMisagh Karimi
Misagh Karimi
CWChongkai Wang
Chongkai Wang
BBBahareh Bahadini
Bahareh Bahadini
GHGeorge Hajjar
George Hajjar
MFMarwan Fakih
Marwan Fakih
Colorectal cancer (CRC) management continues to evolve. In metastatic CRC, several clinical and molecular biomarkers are now recommended to guide treatment decisions. Primary tumor location (right versus left) has been shown to predict benefit from anti-epidermal growth factor receptors (EGFRs) in rat sarcoma viral oncogene homologue (RAS) and v-raf murine sarcoma viral oncogene homolog B1 (BRAF) wild-type patients. Anti-EGFR therapy has not resulted in any benefit in RAS-mutated tumors, irrespective of the primary tumor location. BRAF-V600E mutations have been associated with poor prognosis and treatment resistance but may benefit from a combination of anti-EGFR therapy and BRAF inhibitors. Human epidermal growth factor receptor 2 (HER-2) amplification was recently shown to predict relative resistance to anti-EGFR therapy but a response to dual HER-2 targeting within the RAS wild-type population. Finally, the mismatch repair (MMR)-deficient subgroup benefits significantly from immunotherapeutic strategies. In addition to the increasingly complex biomarker landscape in CRC, metastatic CRC remains one of the few malignancies that benefits from metastasectomies, ablative therapies, and regional hepatic treatments. This treatment complexity requires a multi-disciplinary approach to treatment and close collaborations between various stakeholders in large cancer center networks. Here, we describe the City of Hope experience and strategy to enhance colorectal cancer care across its network.